Patient Research
Sign in
All studies
RecruitingOBSERVATIONAL

Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

This study, based in Strasbourg, France, is exploring how many adults with cystic fibrosis (CF) currently smoke or use e-cigarettes (vape). For a long time, it was thought that people with CF didn't smoke, but there's a lack of up-to-date information on this in France. With significant improvements in CF care, including better quality of life and longer life expectancy, understanding smoking and vaping habits is now more important than ever. The study aims to gather this vital information to help develop better programmes to stop people with CF from smoking or vaping. This is particularly relevant as new international research is looking at how smoking and vaping might affect the effectiveness of important CF medicines like Kaftrio.

At a glance

Status
Recruiting
Sponsor
University Hospital, Strasbourg, France
Enrolment target
100
Start
15 Oct 2025
Estimated completion
15 Oct 2026
Cystic Fibrosis

What is this study about?

This study is designed to find out how many adults living with cystic fibrosis (CF) in Strasbourg, France, currently smoke regular cigarettes or use e-cigarettes (vape). For a long time, it was generally believed that people with CF didn't smoke. Because of this long-held idea, there hasn't been much research in France about how common smoking is among people with CF.

However, things are changing for people with cystic fibrosis. Modern treatments have led to a much better quality of life, longer life expectancy, fewer urgent hospital visits, and better overall health. With these positive changes, it’s really important to get an up-to-date picture of smoking and vaping habits within the CF community. Knowing this information will help doctors and healthcare providers create more effective programmes to prevent people with CF from starting to smoke or vape, or to help them stop if they already do.

This research is even more important because new studies from around the world are starting to look into how smoking and vaping might affect how well new CF medications, such as Kaftrio, work. Understanding the link between smoking, vaping, and these powerful new treatments could help improve care for many people with CF.

Key takeaways

  • The study focuses on smoking and vaping in adults with cystic fibrosis.
  • It aims to improve prevention efforts in this group.
  • It's for adults (18+) with CF in Strasbourg, France.
  • No new medicines or treatments are involved.
  • Results could help improve future CF care and prevention programmes.

Who may be eligible?

To be part of this study, you need to be an adult, which means you must be 18 years old or older. You also need to have a confirmed diagnosis of cystic fibrosis.

Additionally, you must be receiving regular care and check-ups at the Adult Cystic Fibrosis Centre in Strasbourg. This ensures that the researchers can easily reach you and that your medical history is well-known to the centre.

However, if you have had a double lung transplant because of your cystic fibrosis, you would not be able to join this particular study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years old or older.
  2. I have been diagnosed with cystic fibrosis.
  3. I receive regular care at the Strasbourg Adult Cystic Fibrosis Centre.
  4. I have NOT had a double lung transplant for my cystic fibrosis.
Answer every question to see your result.

What does participation involve?

The study does not involve taking any new medications, having extra doctor's visits, or undergoing specific tests beyond your usual care. It aims to gather information through surveys or existing medical records. Therefore, there are no specific details provided about visits, assessments, or follow-up that would be different from your standard care. The total duration of your involvement is not specified, but it's likely a one-off assessment or data collection.

Potential risks and benefits

There are no significant risks associated with taking part in this study, as it primarily involves collecting information rather than medical interventions. A potential benefit is that the information gathered will help healthcare professionals better understand smoking and vaping trends among people with CF, leading to improved prevention strategies and possibly better care in the future. You have the right to withdraw from the study at any time without giving a reason, and this would not affect your ongoing medical care.

Locations (1)

  • Service de Pneumologie - CHU de Strasbourg - France
    Verified postcode
    Strasbourg, France· Recruiting

Common questions

What is this study about?

It's looking at how many adults with cystic fibrosis in Strasbourg, France, smoke or use e-cigarettes to help improve prevention.

Why is this study important now?

Because new CF treatments mean people are living longer and healthier lives, so understanding lifestyle choices like smoking is crucial.

Will I have to take any new medicines?

No, this study does not involve any new medicines or specific treatments.

Who can take part?

Adults (18+) with cystic fibrosis who are regularly seen at the Strasbourg Adult CF Centre.

What if I've had a lung transplant?

If you've had a double lung transplant for CF, you won't be able to join this study.

How to find out more

Romain Kessler, MD, PhD

romain.kessler@chru-strasbourg.fr 33 3 69 55 03 77 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Study of the Prevalence of Active/Passive Smoking and Vaping…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.